Literature DB >> 11865139

Three novel COLQ mutations and variation of phenotypic expressivity due to G240X.

Y A Shapira1, M E Sadeh, M P Bergtraum, A Tsujino, K Ohno, X M Shen, J Brengman, S Edwardson, I Matoth, A G Engel.   

Abstract

OBJECTIVE: To determine the molecular basis and consequences of endplate (EP) acetylcholinesterase (AChE) deficiency.
BACKGROUND: The EP species AChE is an asymmetric enzyme consisting of a tail subunit composed of three collagenic strands (ColQ), each attached to a tetramer of catalytic subunits. The tail subunit is essential for insertion of AChE into the synaptic basal lamina. Human EP AChE deficiency is caused by mutations in COLQ. The authors report three novel COLQ mutations in eight kinships.
METHODS: Immunocytochemistry, electron microscopy, microelectrode recordings, mutation analysis, and expression studies in COS cells were employed.
RESULTS: Two mutations (275insC and Q211X) were heterozygous in one patient. EP studies in this patient revealed no EP AChE, small nerve terminals, reduced presynaptic membrane length, as well as abnormally low-evoked quantal release. The third mutation (G240X) was homozygous in six Palestinian Arab families of the same tribe and in an Iraqi Jewish patient. Expression studies of the three mutations in COS cells indicate that each abrogates formation of insertion competent asymmetric AChE. Although the three mutations have identical predicted consequences at the EP, their phenotypic expressivity varies as regards age at onset, rate of progression, and severity of symptoms.
CONCLUSIONS: 1) After mutations in the AChR epsilon subunit, mutations in COLQ are emerging as second most common cause of congenital myasthenic syndromes. 2) A founder effect is likely for G240X in the Palestinian Arab families. 3) That mutations predicting total absence of AChE from the EP have variable phenotypic expressivity suggests that modifying genes or environmental factors can partially compensate for EP AChE deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865139     DOI: 10.1212/wnl.58.4.603

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Trimerization domain of the collagen tail of acetylcholinesterase.

Authors:  Suzanne Bon; Annick Ayon; Jacqueline Leroy; Jean Massoulié
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

2.  Functional consequences and structural interpretation of mutations of human choline acetyltransferase.

Authors:  Xin-Ming Shen; Thomas O Crawford; Joan Brengman; Gyula Acsadi; Susan Iannaconne; Emin Karaca; Chaouky Khoury; Jean K Mah; Shimon Edvardson; Zeljko Bajzer; David Rodgers; Andrew G Engel
Journal:  Hum Mutat       Date:  2011-09-23       Impact factor: 4.878

3.  Congenital myasthenic syndrome in Israel: Genetic and clinical characterization.

Authors:  Sharon Aharoni; Menachem Sadeh; Yehuda Shapira; Simon Edvardson; Muhannad Daana; Talia Dor-Wollman; Aviva Mimouni-Bloch; Ayelet Halevy; Rony Cohen; Liora Sagie; Zohar Argov; Malcolm Rabie; Ronen Spiegel; Ilana Chervinsky; Naama Orenstein; Andrew G Engel; Yoram Nevo
Journal:  Neuromuscul Disord       Date:  2016-11-24       Impact factor: 4.296

4.  Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol.

Authors:  Sophelia H S Chan; Virginia C N Wong; Andrew G Engel
Journal:  Pediatr Neurol       Date:  2012-08       Impact factor: 3.372

5.  Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals.

Authors:  Haipeng Zhu; Bula Bhattacharyya; Hong Lin; Christopher M Gomez
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

Review 6.  The spectrum of congenital myasthenic syndromes.

Authors:  Andrew G Engel; Kinji Ohno; Steven M Sine
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

7.  Congenital myasthenic syndromes: Natural history and long-term prognosis.

Authors:  Sujit Abajirao Jagtap; Kuruvilla Abraham; C Sarada; M D Nair
Journal:  Ann Indian Acad Neurol       Date:  2013-07       Impact factor: 1.383

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.